Loading...
For patients with metastatic gastric cancer who experience disease progression after first-line treatment, second-line chemotherapy with taxanes or irinotecan confers a modest benefit in disease control and survival. Trastuzumab, the only approved targeted agent in gastric cancer, improves survival when combined with chemotherapy in human epidermal growth factor receptor-2 (HER2)-positive disease (Lancet 2010; 376:687). Bevacizumab, which targets the vascular endothelial growth factor (VEGF) A ligand of VEGF receptor 2, failed to improve survival in a global phase III trial when added to chemotherapy.
Now, investigators from China report the results of an industry-sponsored, multicenter, randomized, placebo-controlled, phase II trial that ev…